Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies

被引:14
作者
Jobski, Kathrin [1 ]
Hoffmann, Falk [1 ]
Herget-Rosenthal, Stefan [2 ]
Doerks, Michael [1 ]
机构
[1] Carl von Ossietzky Univ Oldenburg, Dept Hlth Serv Res, Ammerlander Heerstr 114-118, D-26129 Oldenburg, Germany
[2] Rotes Kreuz Hosp, Dept Med, Bremen, Germany
关键词
Anticoagulants; Drug interactions; Risk of bleeding; Nursing home residents; ATRIAL-FIBRILLATION; GASTROINTESTINAL-TRACT; VENOUS THROMBOEMBOLISM; USE PATTERNS; RISK; WARFARIN; RIVAROXABAN; THERAPY; TRENDS; PHENPROCOUMON;
D O I
10.1007/s00392-019-01526-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Vitamin K antagonists (VKAs) are susceptible to drug-drug interactions. Non-VKA oral anticoagulants (NOACs) have a decreased sensitivity to pharmacokinetic interactions and might be therefore considered superior in patients treated with multiple drugs. The objective of this study was to compare the risk of serious bleeding associated with interacting drugs in German nursing home residents treated with VKA or NOAC. Methods Using claims data of new nursing home residents aged >= 65 years (2010-2014) we conducted separate nested case-control analyses within two cohorts of patients treated with VKA or NOAC, respectively. Cases were defined as patients hospitalized for serious bleeding. For each case, up to 20 controls were selected by risk-set sampling. Conditional logistic regression was used to obtain confounder-adjusted odds ratios (aORs) and 95% confidence intervals (CI) for the risk of bleeding associated with VKA or NOAC use and interacting drugs compared with the use of the respective oral anticoagulant alone. Results Among 127,227 new nursing home residents, 16,804 patients received oral anticoagulation. Based on 372 cases and 7281 matched controls, the highest risk of bleeding in VKA users was observed for the concomitant use of antibiotics (aOR 3.00; CI 2.11-4.27) vs. VKA use alone, followed by non-steroidal anti-inflammatory drugs (1.66; 1.13-2.43). Among 243 NOAC cases and 4776 matched controls, elevated risks for bleeding were observed for the use of heparins (2.05; 1.25-3.36) and platelet inhibitors (1.92; 1.36-2.72). Conclusions Concomitant medication needs to be prescribed cautiously and monitored closely in nursing home residents treated with oral anticoagulants. Graphic
引用
收藏
页码:465 / 475
页数:11
相关论文
共 50 条
[31]   Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting [J].
Dincq, Anne-Sophie ;
Lessire, Sarah ;
Douxfils, Jonathan ;
Dogne, Jean-Michel ;
Gourdin, Maximilien ;
Mullier, Francois .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[32]   Misdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Primary Care [J].
Cardoso, Carlos Seica ;
Sousa, Joao Andre ;
Simoes, Pedro ;
Silva, Beatriz ;
Albuquerque, Ana ;
Esperanca, Ana ;
Cibrao, Ana ;
Correia, Artur ;
Goncalves, Joana ;
Mortagua, Joana ;
Almeida, Jose Eduardo ;
Oliveira, Leonor ;
Garcia, Jose ;
Duarte, Mariana ;
Loureiro, Mariana ;
Costa e Silva, Marta ;
Fraga, Marta ;
Lopes, Paulo ;
Brandao, Rui ;
Miguel, Susana ;
Queiros, Teresa ;
Santo, Gustavo ;
Silva, Fernando ;
Sargento-Freitas, Joao .
CLINICAL THERAPEUTICS, 2020, 42 (06) :1132-+
[33]   Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease [J].
Mongeon, Francois-Pierre ;
Macle, Laurent ;
Beauchesne, Luc M. ;
Bouma, Berto J. ;
Schwerzmann, Markus ;
Mulder, Barbara J. M. ;
Khairy, Paul .
CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (12) :1686-1697
[34]   Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease [J].
Al Said, Samer ;
Ellscheid, Michael ;
Beltsios, Eleftherios T. ;
Frey, Norbert .
HAMOSTASEOLOGIE, 2022, 42 (03) :201-209
[35]   Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation [J].
Basaran, Ozcan ;
Dogan, Volkan ;
Sahin, Cem ;
Biteker, Murat .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 :357-357
[36]   Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage [J].
Chen, Szu-Ju ;
Yeh, Shin-Joe ;
Tang, Sung-Chun ;
Lin, Shin-Yi ;
Tsai, Li-Kai ;
Jeng, Jiann-Shing .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (01) :106-112
[37]   Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory [J].
Blann, A. D. .
BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) :158-167
[38]   Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation [J].
Undas, Anetta ;
Drabik, Leszek .
ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (01) :10-18
[39]   Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia [J].
Janion-Sadowska, Agnieszka ;
Papuga-Szela, Elbieta ;
Lukaszuk, Robert ;
Chrapek, Magdalena ;
Undas, Anetta .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) :153-160
[40]   Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends [J].
Shiyovich, Arthur ;
Shalev, Varda ;
Chodick, Gabriel ;
Tirosh, Matanya ;
Katz, Amos ;
Klar, Miriam M. ;
Shuvy, Mony ;
Pereg, David ;
Minha, Sa'ar .
BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)